ARRDC3 regulates the targeted therapy sensitivity of clear cell renal cell carcinoma by promoting AXL degradation

References

• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. doi: 10.3322/caac.21654
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi: 10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Kane CJ, Mallin K, Ritchey J, et al. Renal cell cancer stage migration: analysis of the national cancer data base. Cancer. 2008;113(1):78–83. doi: 10.1002/cncr.23518
   PubMed Web of Science ®Google Scholar
• Dabestani S, Thorstenson A, Lindblad P, et al. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J Urol. 2016;34(8):1081–1086. doi: 10.1007/s00345-016-1773-y
   PubMed Web of Science ®Google Scholar
• Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. doi: 10.1186/s12943-018-0782-4
   PubMed Web of Science ®Google Scholar
• Molina AM, Lin X, Korytowsky B, et al. Sunitinib objective response in metastatic renal cell carcinoma: analysis of 1059 patients treated on clinical trials. Eur J Cancer. 2014;50(2):351–358. doi: 10.1016/j.ejca.2013.08.021
   PubMed Web of Science ®Google Scholar
• Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000. doi: 10.1016/S1470-2045(09)70240-2
   PubMed Web of Science ®Google Scholar
• Lim SH, Hwang IG, Ji JH, et al. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia Pac J Clin Oncol. 2017;13(1):61–67. doi: 10.1111/ajco.12465
   PubMed Web of Science ®Google Scholar
• Qi S, O’Hayre M, Gutkind JS, et al. Structural and biochemical basis for ubiquitin ligase recruitment by arrestin-related domain-containing protein-3 (ARRDC3). J Biol Chem. 2014;289(8):4743–4752. doi: 10.1074/jbc.M113.527473
   PubMed Web of Science ®Google Scholar
• Han SO, Kommaddi RP, Shenoy SK. Distinct roles for β-arrestin2 and arrestin-domain-containing proteins in β 2 adrenergic receptor trafficking. EMBO Rep. 2013;14(2):164–171. doi: 10.1038/embor.2012.187
   PubMed Web of Science ®Google Scholar
• Soung YH, Pruitt K, Chung J. Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells. Sci Rep. 2014;4(1):3846. doi: 10.1038/srep03846
   PubMedGoogle Scholar
• Xiao J, Shi Q, Li W, et al. ARRDC1 and ARRDC3 act as tumor suppressors in renal cell carcinoma by facilitating YAP1 degradation. Am J Cancer Res. 2018;8(1):132–143.
   PubMed Web of Science ®Google Scholar
• Zheng Y, Lin ZY, Xie JJ, et al. ARRDC3 inhibits the progression of human prostate cancer through ARRDC3-ITGβ4 pathway. Curr Mol Med. 2017;17(3):221–229. doi: 10.2174/1566524017666170807144711
   PubMed Web of Science ®Google Scholar
• Chen Y, Tian D, Chen X, et al. ARRDC3 as a diagnostic and prognostic biomarker for epithelial ovarian cancer based on data mining. Int J Gen Med. 2021;14:967–981. doi: 10.2147/IJGM.S302012
   PubMed Web of Science ®Google Scholar
• Wedegaertner H, Pan WA, Gonzalez CC, et al. The α-arrestin ARRDC3 is an emerging multifunctional adaptor protein in cancer. Antioxid Redox Signal. 2022;36(13–15):1066–1079. doi: 10.1089/ars.2021.0193
   PubMed Web of Science ®Google Scholar
• Soung YH, Ford S, Yan C, et al. The role of arrestin domain-containing 3 in regulating endocytic recycling and extracellular vesicle sorting of integrin β4 in breast cancer. Cancers (Basel). 2018;10(12):507. doi: 10.3390/cancers10120507
   PubMed Web of Science ®Google Scholar
• Shen X, Sun X, Sun B, et al. ARRDC3 suppresses colorectal cancer progression through destabilizing the oncoprotein YAP. FEBS Lett. 2018;592(4):599–609. doi: 10.1002/1873-3468.12986
   PubMed Web of Science ®Google Scholar
• Arakaki AKS, Pan WA, Lin H, et al. The α-arrestin ARRDC3 suppresses breast carcinoma invasion by regulating G protein–coupled receptor lysosomal sorting and signaling. J Biol Chem. 2018;293(9):3350–3362. doi: 10.1074/jbc.RA117.001516
   PubMed Web of Science ®Google Scholar
• Graham DK, DeRyckere D, Davies KD, et al. The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer. Nat Rev Cancer. 2014;14(12):769–785. doi: 10.1038/nrc3847
   PubMed Web of Science ®Google Scholar
• Corno C, Gatti L, Lanzi C, et al. Role of the receptor tyrosine kinase axl and its targeting in cancer cells. Curr Med Chem. 2016;23(15):1496–1512. doi: 10.2174/0929867323666160405112954
   PubMed Web of Science ®Google Scholar
• Qu L, Ding J, Chen C, et al. Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA. Cancer Cell. 2016;29(5):653–668. doi: 10.1016/j.ccell.2016.03.004
   PubMed Web of Science ®Google Scholar
• Zhou L, Liu XD, Sun M, et al. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma. Oncogene. 2016;35(21):2687–2697. doi: 10.1038/onc.2015.343
   PubMed Web of Science ®Google Scholar
• Colavito SA. AXL as a target in breast cancer therapy. J Oncol. 2020;2020:5291952. doi: 10.1155/2020/5291952
   PubMedGoogle Scholar
• Paolino M, Choidas A, Wallner S, et al. The E3 ligase cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature. 2014;507(7493):508–512. doi: 10.1038/nature12998
   PubMed Web of Science ®Google Scholar
• Valverde P. Effects of Gas6 and hydrogen peroxide in axl ubiquitination and downregulation. Biochem Biophys Res Commun. 2005;333(1):180–185. doi: 10.1016/j.bbrc.2005.05.086
   PubMed Web of Science ®Google Scholar
• Kwon YT, Ciechanover A. The ubiquitin code in the ubiquitin-proteasome system and autophagy. Trends Biochem Sci. 2017;42(11):873–886. doi: 10.1016/j.tibs.2017.09.002
   PubMed Web of Science ®Google Scholar
• Shi H, Sun Y, He M, et al. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression. Oncogene. 2020;39(3):530–545. doi: 10.1038/s41388-019-0962-8
   PubMed Web of Science ®Google Scholar
• Ghiso E, Migliore C, Ciciriello V, et al. YAP-dependent AXL overexpression mediates resistance to EGFR inhibitors in NSCLC. Neoplasia. 2017;19(12):1012–1021. doi: 10.1016/j.neo.2017.10.003
   PubMed Web of Science ®Google Scholar
• Auyez A, Sayan AE, Kriajevska M, et al. AXL receptor in cancer metastasis and drug resistance: when normal functions go askew. Cancers (Basel). 2021;13(19):4864. doi: 10.3390/cancers13194864
   PubMed Web of Science ®Google Scholar
• Stone L. Kidney cancer: AXL expression predicts prognosis. Nat Rev Urol. 2017;14(12):700. doi: 10.1038/nrurol.2017.186
   PubMed Web of Science ®Google Scholar